O6-methylguanine-induced transcriptional mutagenesis reduces p53 tumor-suppressor function. 2018

Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
Unit of Biochemical Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Altered protein function due to mutagenesis plays an important role in disease development. This is perhaps most evident in tumorigenesis and the associated loss or gain of function of tumor-suppressor genes and oncogenes. The extent to which lesion-induced transcriptional mutagenesis (TM) influences protein function and its contribution to the development of disease is not well understood. In this study, the impact of O6-methylguanine on the transcription fidelity of p53 and the subsequent effects on the protein's function as a regulator of cell death and cell-cycle arrest were examined in human cells. Levels of TM were determined by RNA-sequencing. In cells with active DNA repair, misincorporation of uridine opposite the lesion occurred in 0.14% of the transcripts and increased to 14.7% when repair by alkylguanine-DNA alkyltransferase was compromised. Expression of the dominant-negative p53 R248W mutant due to TM significantly reduced the transactivation of several established p53 target genes that mediate the tumor-suppressor function, including CDKN1A (p21) and BBC3 (PUMA). This resulted in deregulated signaling through the retinoblastoma protein and loss of G1/S cell-cycle checkpoint function. In addition, we observed impaired activation of apoptosis coupled to the reduction of the tumor-suppressor functions of p53. Taking these findings together, this work provides evidence that TM can induce phenotypic changes in mammalian cells that have important implications for the role of TM in tumorigenesis.

UI MeSH Term Description Entries
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D006147 Guanine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016296 Mutagenesis Process of generating a genetic MUTATION. It may occur spontaneously or be induced by MUTAGENS. Mutageneses
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D059585 G1 Phase Cell Cycle Checkpoints Regulatory signaling systems that control the progression of the CELL CYCLE through the G1 PHASE and allow transition to S PHASE when the cells are ready to undergo DNA REPLICATION. DNA DAMAGE, or the deficiencies in specific cellular components or nutrients may cause the cells to halt before progressing through G1 phase. G1 Cell Cycle Arrest,G1 Cell Cycle Checkpoints,G1 Phase Checkpoints,G1 Phase Restriction Point,G1 Restriction Point,G1-S Phase Cell Cycle Checkpoint,START Cell Cycle Checkpoint,Checkpoint, G1 Phase,Checkpoints, G1 Phase,G1 Phase Checkpoint,G1 Restriction Points,G1 S Phase Cell Cycle Checkpoint,Restriction Point, G1,Restriction Points, G1

Related Publications

Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
January 1984, Nature,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
November 1999, Mutation research,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
August 1995, Carcinogenesis,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
January 1998, Seminars in cancer biology,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
June 2017, International journal of cancer,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
April 2000, Frontiers in bioscience : a journal and virtual library,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
July 1991, Biochemistry,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
January 2007, Cancer research,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
November 1996, The Journal of biological chemistry,
Monika Ezerskyte, and João A Paredes, and Stefano Malvezzi, and John A Burns, and Geoffrey P Margison, and Magnus Olsson, and David A Scicchitano, and Kristian Dreij
May 2005, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!